Bayer (BAYRY) announces the initiation of the phase II, ALPINE-1 study, on pipeline candidate BAY3283142 following the successful first-in-human trials. BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, is being evaluated for patients with chronic kidney disease (CKD). APLINE-1 is a randomized, double-blind, placebo-controlled, multicenter study that will assess the efficacy and safety of BAY3283142 in CKD patients. CKD is a progressive condition affecting more than 10% of the global ...